ABSTRACT
Background: Enterobacter were proposed as a genus in 1960 by Hormaeche and Edwards based on the division of the former genus Aerobacter into motile, ornithine decarboxylase (ODC)–positive strains (Enterobacter) and nonmotile ODC-negative strains (Klebsiella). The Vitek-2 system is the second generation of Vitek and offers a more sophisticated model of data analysis as well as a fully automated process for card identification, organism suspension dilution and card filling. To study Aim and Objectives: identification and antimicrobial susceptibility pattern of Enterobacter species by Vitek-2 system isolated from various clinical samples. Material and Methods: A total of 100 Enterobacter species obtained from various clinical samples like urine, pus, sputum, endotracheal aspirate and body fiuids (pleural, ascitic, peritoneal and CSF) etc. of patients received at Department of Microbiology, Government Medical College & Associated Group of Hospitals, Kota during a period of approximately 1 year from May 2021 to May 2022 were taken for the identification and Antibiotic sensitivity testing by Vitek-2 system. Out of 100 Enterobacter isolates, 69% w Result: ere E.cloacae and 31% were E.aerogenes. Antimicrobial susceptibility results of Enterobacter species revealed the susceptibility of 56.41% for Nitrofurantoin, 69% for Piperacillin/ Tazobactam and 72% for Cefoperazone/ salbactam. Enterobacter seems to be emerged with increasi Conclusion: ng resistance to multiple antibiotics.
ABSTRACT
El objetivo de este trabajo fue evaluar los resultados de sensibilidad a los antifúngicos de diversas especies de Candida utilizando el sistema semiautomatizado Vitek 2 (tarjetas AST-YSO1; bioMérieux), y compararlos con los obtenidos por el método de referencia del Clinical and Laboratory Standards Institute (CLSI), la microdilución en caldo (Documento M27-A3, 2008). La concordancia esencial fue > 90 %, excepto en el caso de Candida glabrata frente al voriconazol (VCZ) y de Candida krusei frente al fluconazol (FCZ). La concordancia global por categoría (variación no mayor que 2 diluciones, sin discriminar por especie) fue > 90 % cuando se evaluó el FCZ, y 89,5 % a las 24 h y 80,7 % a las 48 h con el VCZ. El tiempo promedio para obtener los resultados fue de 15,5 h. Los errores menores (sensible o resistente por un método y dosis dependiente por el otro) para FCZ fueron de 7,8 % a las 24 h y 6,1 % a las 48 h; para VCZ, 10,5 % a las 24 h y 19,3 % a las 48 h. Solo se detectó 1 error muy mayor (resistente por el método de referencia y sensible por Vitek 2) con Candida parapsilosis frente a FCZ a las 48 h. No se observaron errores mayores (sensibles por el método de referencia y resistentes por Vitek 2). Con respecto a la anfotericina B, solo 3 cepas presentaron una CIM = 2 ?g/ml. El sistema Vitek 2 detectó correctamente el valor de CIM para diversas especies de Candida y presentó una excelente concordancia con el método de referencia propuesto por el CLSI.
The aim of this investigation was to evaluate the results of antifungal susceptibility for various Candida species using the Vitek 2 semi-automated system (AST-YSO1 cards, bioMérieux), and to compare them with those obtained by the CLSI (Clinical and Laboratory Standards Institute) broth microdilution reference method (Document M27-A3,2008). The essential agreement (EA) was > 90%, except for Candida glabrata against voriconazole (VCZ); and for Candida krusei against fluconazole (FCZ). The overall categorical agreement (CA) was > 90% when FCZ was evaluated and 89.5% at 24 h and 80.7% at 48 h for VCZ. The average time for obtaining results was 15.5 h. Minor errors were 7.8% at 24 h and 6.1% at 48 h for FCZ, and 10.5% at 24 h and 19.3% at 48 h for VCZ. There was only one very major error for FCZ against Candida parapsilosis and no major errors were observed. For amphotericin B, only three isolates showed MICs = 2 ?g/ml. The Vitek 2 system detected the MIC value for various Candida species and showed excellent agreement with the reference method proposed by the CLSI.
Subject(s)
Humans , Amphotericin B/pharmacology , Antifungal Agents/pharmacology , Candida/drug effects , Fluconazole/pharmacology , Pyrimidines/pharmacology , Triazoles/pharmacology , Microbial Sensitivity Tests , Mycology/methods , VoriconazoleABSTRACT
BACKGROUND: The rapid emergence of multi-drug resistant pneumococcal strains has heightened the importance of reliable and convenient susceptibility testing methods. The newly-developed VITEK-2 (bioMerieux, Inc., Hazelwood, MO, USA) System includes the capability of performing rapid susceptibility testing of Streptococcus pneumoniae using specially configured cards. The objective of this study is to evaluate the performance of the VITEK-2 System for susceptibility testing of S. pneumoniae. METHODS: One hundred clinical strains of S. pneumoniae (18 penicillin susceptible strains, 32 intermediate strains, and 50 resistant strains) were tested, which had been isolated in Samsung Medical Center. Minimum inhibitory concentrations (MICs) for penicillin, cefotaxime, erythromycin, ofloxacin, chloramphenicol, tetracyclin, and vancomycin were determined by broth dilution method and VITEK-2 System using AST-P506 cards. The results obtained by VITEK-2 System were compared to those obtained by broth dilution method. RESULTS: Overall agreement of MICs determined by two methods was 93.0% within the range of one dilution. The best agreement was achieved with vancomycin (100%), and in descending order, 99% with ofloxacin, 97% with erythromycin, 94% with chloramphenicol, 89% with cefotaxime, 88% with tetracycline, and 85% with penicillin. There were 1.9% of very major error, 2.0% of major error, and 8.6% of minor error. The mean time for generation of susceptibility results was 9.6 hours. CONCLUSIONS: VITEK-2 System provided rapid and reliable determinations of susceptibility category for most antibiotics and would be helpful as a substitution of existing MIC methods.